Estimated reading time: 3 minutes
Key Takeaways
- James Van Der Beek, known for Varsity Blues, advocates for colorectal cancer screening awareness.
- He partnered with Guardant Health to promote the innovative Shield™ blood test, a non-invasive screening tool.
- The Shield™ blood test is FDA-approved for adults aged 45 and older and may improve screening adherence.
- This initiative aims to catch colorectal cancer early, increasing survival rates through accessible testing options.
- Public awareness efforts are vital as screening guidelines shift to include younger adults, potentially saving more lives.
Table of Contents
Why James Van Der Beek’s New Advocacy Matters Now
Colorectal Cancer: The Crucial Context
Introducing the Shield™ Blood Test: A Game-Changer in Screening
Wider Impact and Future Directions
Why James Van Der Beek’s New Advocacy Matters Now
James Van Der Beek, best known for his iconic role in Varsity Blues, is stepping into the spotlight not for acting, but as a passionate health advocate. In July 2025, Van Der Beek partnered with Guardant Health, a leading precision oncology company, to raise awareness about innovative colorectal cancer screening options for adults aged 45 and older.
Colorectal Cancer: The Crucial Context
Colorectal cancer (CRC) is the second deadliest cancer but also one of the most curable if caught early. Despite this, many adults delay or skip screening, which can be life-threatening. Van Der Beek revealed his diagnosis of stage 3 colorectal cancer at age 46—a strong wake-up call about the silent nature of this disease.
“I was in great physical shape and never imagined I had cancer. Screening saved my life,” says Van Der Beek.
Introducing the Shield™ Blood Test: A Game-Changer in Screening
Guardant Health’s Shield™ blood test, FDA approved last year, offers a more convenient, less invasive screening option compared to traditional colonoscopies. This blood test aims to improve adherence among hesitant adults who avoid screening due to discomfort or inconvenience.
- Approved by FDA for screening adults 45+ for colorectal cancer
- Non-invasive, blood-based alternative to colonoscopy
- Designed to increase early detection rates and save lives
Van Der Beek emphasized, “If you’re 45 or older, talk to your doctor about screening options like Shield. It could save your life.”
Wider Impact and Future Directions
This collaboration comes amid broader efforts by Guardant Health to expand precision oncology testing. The company is also partnering with healthcare providers in North America to broaden access to advanced cancer detection tests.
Van Der Beek’s involvement brings star power to a critical health issue, potentially influencing millions to take action. His openness underscores the importance of transparency in battling cancer stigma and advancing public health.
What This Means for You
- If you’re 45+, don’t delay screening. Speak with your healthcare provider about the new Shield blood test and other colorectal cancer screening options.
- Awareness and early detection remain key — this partnership highlights innovation that can transform public health outcomes.
In Summary
James Van Der Beek’s brave and heartfelt campaign with Guardant Health shines a spotlight on colorectal cancer screening innovations just as guidelines shift for younger adults. With accessible new tools like the Shield blood test, more people may overcome screening barriers and catch cancer before symptoms arise. This moment is a powerful reminder: Early screening saves lives.
FAQ
Why is screening important for colorectal cancer?
Screening can detect colorectal cancer early when it is most treatable, significantly increasing survival rates. It also helps identify precancerous conditions, preventing cancer development altogether.
How does the Shield™ blood test work?
The Shield™ blood test is a non-invasive, blood-based screening tool approved by the FDA. It analyzes circulating tumor DNA to detect early signs of colorectal cancer, offering a convenient alternative to colonoscopy.
Who should consider getting screened?
Adults aged 45 and older, especially those with a family history or at increased risk, should discuss screening options with their healthcare provider. The newer guidelines recommend starting earlier than before.
- Talk to your doctor about the Shield blood test and other screening options
- Early detection is key to successful treatment